Physician profile
Patrick B Fenlon
NPI 1841259934
$1,528.06
in general payments reported to CMS, 2019-2025
23 companies · $23.07 in 2025
The $23.07 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $106 · 2021: $230 · 2022: $308 · 2025: $23.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $304.00 | 2019-2022 | |
| Amgen INC. | $154.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $145.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $136.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.18 | 2019-2021 | |
| Abbvie INC. | $92.42 | 2019-2022 | |
| Pfizer INC. | $87.26 | 2019-2022 | |
| Astellas Pharma US INC | $78.92 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $70.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $43.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.75 | 2022 | |
| Jazz Pharmaceuticals INC. | $32.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.00 | 2019 | |
| Sanofi Pasteur INC. | $24.50 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.07 | 2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $15.53 | 2021 | |
| Abbott Laboratories | $14.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.32 | 2019 | |
| Grifols USA, LLC | $14.29 | 2020 | |
| Insmed, INC. | $13.70 | 2019 | |
| Lilly USA, LLC | $12.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Fenlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.